BridgeBio is advancing its commercial strategy for Attruby and aims to double its patient reach by 2026, reflecting the effectiveness of its decentralized model in driving meaningful healthcare solutions. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy.
Cyborg Score Rationale
Recent positive Phase 3 PROPEL 3 results for infigratinib in achondroplasia demonstrated statistically significant gains with a favorable safety profile, and infigratinib achieved the highest reported absolute annualized height velocity in randomized achondroplasia trials, with FDA/European approvals expected in H2 2026. Attruby rapidly becoming the first-choice therapy for newly diagnosed ATTR-CM patients with 6,629 unique patient prescriptions and $362.4 million in full-year 2025 revenue demonstrates commercial traction. However, high cash burn and execution risks on multiple late-stage programs remain near-term pressures.
Top Insights
February 2026 Phase 3 achondroplasia data breakthrough: infigratinib achieved record annualized height velocity gains with approvals expected H2 2026
Attruby dominance in ATTR-CM with 6,629 patient prescriptions by year-end 2025 and $362.4 million 2025 revenue drives commercial base
Three potential near-term NDA submissions: ADH1 (encaleret, H1 2026), LGMD2I/R9 (BBP-418, H1 2026), and Phase 2 data supporting hypochondroplasia indication
Double patient reach goal by end of 2026 despite negative margins and high debt-to-equity ratio requiring successful launches
Named Competitors
Amgen — Large pharma with rare disease focus and skeletal dysplasia research
Alnylam — RNA interference therapies for genetic diseases